Chandrasekar P H, Smith B R, LeFrock J L, Carr B
Antimicrob Agents Chemother. 1984 Aug;26(2):280-2. doi: 10.1128/AAC.26.2.280.
Patients were given aztreonam (SQ 26,776) parenterally for the treatment of various gram-negative infections. During or shortly after therapy, 8 (17.8%) of 45 patients became infected with or colonized by enterococcus. These eight cases included eight urinary tract isolates; one of these cases subsequently developed bacteremia. Five patients required further antimicrobial therapy directed against enterococcus. Patients receiving aztreonam are at risk for the development of enterococcal superinfection or colonization.
患者接受氨曲南(SQ 26,776)静脉注射治疗各种革兰氏阴性菌感染。在治疗期间或治疗后不久,45名患者中有8名(17.8%)感染了肠球菌或被肠球菌定植。这8例包括8株泌尿道分离株;其中1例随后发生了菌血症。5名患者需要针对肠球菌进行进一步的抗菌治疗。接受氨曲南治疗的患者有发生肠球菌二重感染或定植的风险。